Does starting a GLP-1 agonist in adults with prediabetes provide benefits over usual treatment?doi:10.1097/EBP.0000000000001885Christian D. HoagTori KornelsenChristy M. WeilandJennifer Cherry BohannanWolters KluwerEvidence-Based Practice
[53] Jun, L.S., Millican, R.L., Hawkins, E.D., Konkol, D.L., Showalter, A.D., Christe, M.E., et al. 2015. Absence of glucagon and insulin action reveals a role for the GLP-1 receptor in endog...
[2] Nauck, M. A., & D'Alessio, D. A. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular diabetology, 21(1), 169.https://doi.org/10.1186/s129...
GLP-1 Receptor Agonist and SGLT2 Inhibitor Prescribing in People With Type 1 Diabetes Piaopiao Li, MS1,2; Zhiyan Li, MPH1; Elizabeth Staton, BA3; et al Guillermo E. Umpierrez, MD4; Georgia Davis, MD4; Hui Shao, MD, PhD1,5; Francisco J. Pasquel, MD, MPH1,4 Author ...
New prescriptions of GLP-1 receptor agonists for the treatment of obesity have increased significantly among individuals without type 2 diabetes in the last decade, according to a study inAnnals of Internal Medicine. The recent rise in GLP-1 receptor agonist prescriptions “has resulted ina medicatio...
Pax6:配对盒6;CDX2/3:尾型同源盒2/3;MafB: MAF bZIP转录因子B;cMaf: c-Maf诱导蛋白;NKX2.1:NK2同源盒1;PDX1:胰腺和十二指肠同源盒1;Pax4:配对盒4;CRE:cAMP反应元件;CREB:cAMP反应元件结合蛋白;PPG:前胰高糖素原;HNF3:肝细胞核因子3;Isl1:ISL LIM同源盒1;Preb:催乳素元件结合。
Native human GLP-1 normalizes hyperglycaemia in patients with type 2 diabetes mellitus, but the shortin vivohalf-life of this hormone limits its therapeutic application A number of synthetic GLP-1 receptor agonists, with half-lives between 2–3 h and several days, have been developed for the ...
根据已经公开的数据,我们有理由相信,Tirzepatide相比Semaglutide有着更好的降糖和降体重效果,如果在不久的将来获批上市,它将会成为这个领域的重磅产品。Eli Lilly另辟蹊径,在Dual agonist赛道上扳回一城。 诺和诺德在这个方向自然也早有布局,甚至早于Eli Lilly,他们获得...
Synthetic exendin-4 was named exenatide and, without further modification, was the first GLP-1 receptor agonist approved to treat type 2 diabetes. The detailed background of the (patho)physiology of the incretin system and the history of the development of incretin-based glucose-lowering ...
Notably, the American Diabetes Association advocates for the utilization of GLP-1 RAs with established cardiovascular benefits in patients diagnosed with type 2 diabetes and concurrent cardiovascular disease. While the studies supporting these benefits were not initially focused on kidney health and ...